Larry L. Augsburger, PhD, is a Pharmtech editorial advisory board (EAB) member.
Larry L. Augsburger, PhD
Professor, Department of
Pharmaceutics
University of Maryland
Augsburger is an emeritus professor at the University of Maryland School of Pharmacy. He previously served as the Shangraw Professor of Industrial Pharmacy and Pharmaceutics, chair of the department of pharmaceutics and director of pharmaceutics graduate programs. He has overseen graduate and postdoctoral student research in the areas of design and optimization of immediate release and extended release oral solid dosage forms, the functionality of excipients, the instrumentation of pharmaceutical processing equipment, and botanical dietary supplement product development and quality.
Augsburger established the Drug Development Facility in the school of pharmacy, which later became UPM Pharmaceuticals, Inc., a university-affiliated for-profit firm for developing drugs and manufacturing clinical supplies. A founding father of UPM, he served for five years as its vice-president of pharmaceutical development and manufacture.
He was a principal investigator and directed the research programs of the $12-million University of Maryland-FDA Collaborative Agreements that led to the development of SUPAC regulatory policies for immediate- and modified-release oral solid dosage forms. Augsburger is an elected fellow and former president of the American Association of Pharmaceutical Scientists (AAPS). Among his awards are the Federation Internationale Pharmaceutique (FIP) Industrial Pharmacy medal, the FDA Commissioner's Special Citation, the AAPS Research Achievement Award and the AAPS Outstanding Educator Award.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.